Patents Examined by Sharon X Wen
  • Patent number: 11319380
    Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: May 3, 2022
    Assignee: PRECIGEN, INC.
    Inventors: Helen Sabzevari, Rutul R. Shah
  • Patent number: 11312777
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: April 26, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michelle R. Kuhne, Peter Brams, Dawn M. Tanamachi, Alan J. Korman, Josephine M. Cardarelli
  • Patent number: 11306149
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: April 19, 2022
    Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.
    Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens, James William West
  • Patent number: 11299545
    Abstract: Anti-HLA-C6 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as autoimmune diseases.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: April 12, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Ryan Eberwine, Anne Fourie, Paul H. Kim, Carl L. Manthey, Hong Zhou
  • Patent number: 11286289
    Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: March 29, 2022
    Assignee: ADAPTIMMUNE LIMITED
    Inventors: Nicholas Tribble, William Lawrance, Eleanor Bagg
  • Patent number: 11254753
    Abstract: The present invention relates to variant antibodies and methods of generating said antibodies with a reduced level of binding to process impurities. In particular, the invention describes variant IgG4 antibodies which have been modified in the heavy chain constant region at any one or a combination of amino acids in the region between Kabat residues 203 and 256, wherein the variant IgG4 antibody has a reduced level of binding to host cell protein (HCP), compared to an unmodified IgG4 antibody. The invention also relates to compositions comprising said variant IgG4 antibodies.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: February 22, 2022
    Inventors: Hella Bosteels, Shugui Chen, Kayeleigh Farrow, Richard Kucia-Tran, William John Kenneth Lewis, Andrew S. Thomson, Mark Uden
  • Patent number: 11242396
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Harald Duerr, Christian Klein, Pablo Umana, Alexander Bujotzek, Joerg Zielonka, Christine Trumpfheller, Moritz Rapp, Marine Le Clech
  • Patent number: 11236173
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: February 1, 2022
    Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
  • Patent number: 11220670
    Abstract: In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: January 11, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
  • Patent number: 11213540
    Abstract: In an aspect, the invention relates to compositions, method, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: January 4, 2022
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Jindrich Henry Kopecek, Jiyuan Yang, Te-Wei Chu
  • Patent number: 11208492
    Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: December 28, 2021
    Assignee: BEIJING MABWORKS BIOTECH CO. LTD.
    Inventors: Feng Li, Boyan Zhang, Pei Ye
  • Patent number: 11207329
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 28, 2021
    Assignees: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
  • Patent number: 11208485
    Abstract: Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: December 28, 2021
    Assignee: InhibRx, Inc.
    Inventors: Rajay A. Pandit, John C. Timmer, Angelica N. Sanabria, Florian Sulzmaier, Brendan P. Eckelman
  • Patent number: 11186631
    Abstract: An anti-STAT3 specific antibody and a pharmaceutical composition comprising the same is provided. The anti-STAT3 specific antibody includes a site that specifically binds to STAT3, and further includes a STAT3 site plus a DNA binding site that confer cell penetration ability, and the pharmaceutical composition includes the anti-STAT3 specific antibody as an active ingredient. The STAT3 specific antibody, and particularly the STAT3/DNA dual specific antibody having a dual specific characteristic, contains a DNA binding site that can penetrate cells and specifically bind to DNA in the nucleus, and thus can overcome the limitations of conventional antibody therapeutics that can target only extracellular proteins. The antibody can inhibit transcription factor activity of STAT3 by specifically binding to phosphorylated activated form of STAT3. Thus, the antibody could be used for the development of a therapeutic agent without side effects for various diseases caused by activation of STAT3.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: November 30, 2021
    Assignee: ROPHTBIO, INC.
    Inventors: SungHo Hahm, JinTae Hong
  • Patent number: 11180569
    Abstract: The present invention relates to a CD20 binding antibody which is capable of depleting B cells, and a BLyS binding antibody which is capable of antagonizing BLyS, as a combination for use in the treatment of an autoimmune disorder. The invention also relates to dosages, duration of treatment and time lapses between administration of the CD20 binding antibody which is capable of depleting B cells, and the BLyS binding antibody which is capable of antagonizing BLyS.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: November 23, 2021
    Inventor: Robert B. Henderson
  • Patent number: 11174323
    Abstract: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are the methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: November 16, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Agnes Lo, Chen Xu, Quan Zhu
  • Patent number: 11167011
    Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Also provided are methods of using the compositions.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: November 9, 2021
    Assignees: Enzo Biochem, Inc., Enzo Theuraputics, Inc.
    Inventors: Joshua Rabbani, Xiaofeng Li, James J. Donegan
  • Patent number: 11161909
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: November 2, 2021
    Assignee: NOVARTIS AG
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn
  • Patent number: 11155620
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: October 26, 2021
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., The Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Patent number: 11116839
    Abstract: The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: September 14, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: Gary Swergold